A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Viral Infections, Non-HIV

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Viruses.

Ahmed SF, Quadeer AA, McKay MR

doi: 10.3390/v12030254.

Viral Infections, Non-HIV

Déjà vu: stimulating open drug discovery for SARS-CoV-2

Drug Discov Today.

Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH

doi: 10.1016/j.drudis.2020.03.019.

Viral Infections, Non-HIV

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Protein J.

Yoshimoto FK

doi: 10.1007/s10930-020-09901-4.

Viral Infections, Non-HIV

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Science.

Dai W, Zhang B, Su H, Li J, Zhao Y, Xie X, Jin Z, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang LK, Xu Y, Yang H, Liu H

doi: 10.1126/science.abb4489.

Viral Infections, Non-HIV

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

N Engl J Med.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ

doi: 10.1056/NEJMc2004973.

Viral Infections, Non-HIV

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

Antiviral Res.

Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, Fu L, Dordick JS, Woods RJ, Zhang F, Linhardt RJ

doi: 10.1016/j.antiviral.2020.104873.

Viral Infections, Non-HIV

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Nature.

Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, Cinatl J, Münch C

doi: 10.1038/s41586-020-2332-7.

Viral Infections, Non-HIV

Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space

Heliyon.

Kowalewski J, Ray A

doi: 10.1016/j.heliyon.2020.e04639.

Viral Infections, Non-HIV

A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes

Med Sci Monit.

Stefano ML, Kream RM, Stefano GB

doi: 10.12659/MSM.926016.

Related content

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Déjà vu: stimulating open drug discovery for SARS-CoV-2

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space

A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes